CONSTANT LEVERAGE LONG - ELI LILLY & CO | Market Closed - Euronext Paris 12:30:02 2024-06-28 EDT | ||
| 18.58 EUR | +3.48% |
|
| Current month | +69.15% | ||
| 1 month | +80.64% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 18.75 | +4.43% |
| 24-06-27 | 17.96 | -1.32% |
| 24-06-26 | 18.2 | +1.96% |
| 24-06-25 | 17.84 | +1.05% |
| 24-06-24 | 17.66 | +7.00% |
Real-time Euronext Paris
Last update June 28, 2024 at 12:30 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| WL5NB | |
| ISIN | NLBNPNL2OS18 |
| Date issued | 2024-03-13 |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 19.72 € |
|---|---|
| Lowest since issue | 6.785 € |
| Spread | 0.28 € |
| Spread % | 1.50% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
905.4
USD
Average target price
868.9
USD
Spread / Average Target
-4.03%
- Stock Market
- Certificates
- WL5NB Certificat
